Trials / Completed
CompletedNCT02126358
Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- LG Life Sciences · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemigliptin and/or Rosuvastatin |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2014-04-30
- Last updated
- 2016-10-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02126358. Inclusion in this directory is not an endorsement.